n Germany, the Federal Government has decided to discontinue the reimbursement of short-acting analogue insulins for people with type 1 diabetes. This follows the conclusions of an evidence-based evaluation carried out by the German Institute for Quality and Cost Effectiveness in Health Care Sector (IQWiG) that was submitted to the German Joint Government Committee (G-BA). As the evaluation concluded that these insulins had no added value compared to human insulin, the decision to discontinue reimbursement was based purely on economic grounds. For more info on this international news story… check out the International Diabetes Federation.
Advertisement
